TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03466294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine and Venetoclax
Description: Azacitidine will be given at dose of 75mg/m2 in Cycle 1 days 1-7; repeat in cycle 2 and 3 if no response. Starting on day 2 of cycle 1, venetoclax will be administered orally with doses increased to a target dose of 600 mg (administer 100 mg on day 2, 200 mg on day 3, 400 mg on day 4 and 600 mg on day 5), then 600 mg daily.
Study: NCT00989248

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic and anaerobic capacity use aquatic exercises
Description: Improve aerobic capacity use aquatic exercises in patients with Congestive Heart Failure
Study: NCT04270214

Intervention type: DRUG
Group type: OTHER
Intervention: Dysport Injectable Product
Description: Dysport injections optimized using kinematics
Study: NCT04358003

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol)
Description: Subjects will receive one treatment per day with the D2000 Cartridge for up to 4 hours (treatment cycle) for up to seven (7) days. Treatment may extend beyond 7 days, up to 14 days total, if deemed necessary and useful by the principal investigator (PI). Additional cartridges may be used, if needed, to achieve the maximum daily treatment duration of 4 hours. Each day, before initiating the treatment cycle, pre-treatment chemistry and hematology, coagulation status, and disease severity scores (SOFA, APACHE II) will be collected. Then, immediately following the therapy on each treatment day, post-therapy measurements will also be collected.~Study Exit. Subjects will be exited from the study after the Day 28 follow-up visit which will occur 28 days after Study Day 1. Subjects will be included in the study for a total of 28 days. Subjects may also choose to discontinue at any time or conclude participation at the discretion of the PI or the subject's treating physician.
Study: NCT03399032

Intervention type: DRUG
Intervention: Caspofungin
Description: Each patient will receive: caspofungin i.v. once daily ( 70 mg on the first day, 50 mg on the 2 and 3 day~Blood samples (3 mL) will be collected 2, 4, 8, 12 and 24 hours after each dose of caspofungin for 3 consecutive days.
Study: NCT02217930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WCK 2349

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Study: NCT00689221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilengitide
Description: Cilengitide 2000 milligram (mg) will be administered intravenously twice weekly over 1 hour infusion from Weeks -1 to 77 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason. If considered beneficial in the opinion of the Investigator, continuation of cilengitide treatment will be optional in subjects without disease progression and after Week 77 since start of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide (TMZ) 75 milligram per square meter \[mg/m\^2\] will be administered intravenously once daily from Weeks 1 to 6. From Week 11 onwards, TMZ will be given as maintenance treatment at a dose of 150-200 mg/m\^2 for consecutive 5 days every 4 weeks until Week 34 or until disease progression.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Temozolomide (TMZ) 75 milligram per square meter \[mg/m\^2\] will be administered intravenously once daily from Weeks 1 to 6. From Week 11 onwards, TMZ will be given as maintenance treatment at a dose of 150-200 mg/m\^2 for consecutive 5 days every 4 weeks until Week 34 or until disease progression.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy (RTX) at a dose of 2 gray (Gy) per fraction will be given once daily, 5 days per week from Weeks 1 to 6, total dose 60 Gy.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Radiotherapy (RTX) at a dose of 2 gray (Gy) per fraction will be given once daily, 5 days per week from Weeks 1 to 6, total dose 60 Gy.
Study: NCT05721534

Intervention type: OTHER
Intervention: Medication review
Description: Annual consultation focusing on pharmacological treatment. This specific consultation constituted the intervention. It included a structured review of the patient's health state, in addition to a structured medication review with a focus on appropriate medication and deprescribing.

Intervention type: OTHER
Intervention: Medication review
Description: Annual consultation focusing on pharmacological treatment. This specific consultation constituted the intervention. It included a structured review of the patient's health state, in addition to a structured medication review with a focus on appropriate medication and deprescribing.
Study: NCT04306198

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Osteosynthesis with Trochanteric Fixation Nail (TFN), using a lag screw as a proximal fixation.
Description: Closed reduction and surgical stabilization of intertrochanteric hip fractures using Trochanteric Fixation Nail (TFN), with lag screw as proximal fixation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Osteosynthesis with Trochanteric Fixation Nail (TFN), using a helical blade as a proximal fixation.
Description: Closed reduction and surgical stabilization of intertrochanteric hip fractures using Trochanteric Fixation Nail (TFN), with helical blade as proximal fixation
Study: NCT01579734

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: 1 tablet, 5 mg / day for 5 years

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet day for 5 years
Study: NCT01812655

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Passive Distraction
Study: NCT02718274

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OraQuick ADVANCE HIV I/II test kits, packaged for self-use (manufactured in Thailand)
Description: Community based distribution of self-tests

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OraQuick ADVANCE HIV I/II test kits, packaged for self-use (manufactured in Thailand)
Description: Community based distribution of self-tests

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home-based initiation of ARVs
Description: Home-based initiation of ARVs by study nurse linked to follow-up at clinic
Study: NCT03185481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 mg QD to 15 mg QD PF-06649751
Description: Up titration from 1 mg QD to 15 mg QD PF-06649751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 mg QD to 15 mg QD PF-06649751
Description: Up titration from 3 mg QD to 15 mg QD PF-06649751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7 mg QD to 15 mg QD PF-06649751
Description: Up titration from 7 mg QD to 15 mg QD PF-06649751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15 mg QD PF-06649751
Description: 15 mg QD PF-06649751 remaining at 15 mg QD PF-06649751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study)
Description: Up titration from 1 mg QD to 7 mg QD PF-06649751 for subject at 1 mg QD who were blindly de-escalated in the parent study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study)
Description: Up titration from 3 mg QD to 7 mg QD PF-06649751 for 3 mg QD subjects who were blindly de-escalated in parent study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study)
Description: 7 mg QD to remain at 7 mg QD PF-06649751 for subjects who were blindly de-escalated in parent study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15 mg QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QD
Description: 7mg QD PF-06649751 for subjects assigned to 15 mg QD who were blindly de-escalated to 7 mg QD PF-06649751 in parent study
Study: NCT02801916

Intervention type: OTHER
Group type: OTHER
Intervention: 27.3 grams oat bran
Description: 200 milliliters water plus 27.3 grams OatWell22, a commercial oat bran product containing 22% oat beta-glucan, followed by 119 grams white bread
Study: NCT00212979

Intervention type: OTHER
Intervention: non intervention study
Study: NCT03825614

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: training
Description: plates and therapeutic exercises applied on young adults

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: training
Description: plates and therapeutic exercises applied on young adults
Study: NCT02892006

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Improvisational Comedy
Description: 6 week curriculum in improvisational comedy. Each class meets for 1.5 hours for 6 consecutive weeks.
Study: NCT04492527

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth coaching sessions
Description: Participants will be receiving a 2-month coaching session intervention that will be delivered via telephone or video-conferencing. Each of the 6 sessions will be 30-45minutes long and one-on-one with a student coach. In each session, coaches will review the participants' health behaviours and assess their knowledge about behavioural risks factors for chronic diseases and their current behaviours. The coaches will then provide information about the health risks of poor health behaviours, and benefits of change. Health behavioural goals will be established through a collaborative process. The coaches will then assist participants to develop readily achievable action plans that participants will follow in between coaching sessions as a means to realize their health goals. Adherence and modifications to the action plans will be discussed at the follow-up coaching session to promote health accountability.
Study: NCT00439712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine
Description: 1 tablet of Levocetirizine 5 mg OD in the morning for 29+/-4 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 placebo tablet OD in the morning for 29+/-4 days
Study: NCT03079154

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teacher-led MBCT course
Description: 9 x 2 hour group sessions following national guidelines for mindfulness-based cognitive therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-guided MBCT course
Description: 9 weeks of self-guided mindfulness-based cognitive therapy, following an audiobook covering the same material and exercises as the teacher-led intervention
Study: NCT01428076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polidocanol Endovenous Microfoam (PEM)
Description: Pharmacokinetic comparison of different doses of drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polidocanol Endovenous Microfoam (PEM)
Description: Pharmacokinetic comparison of different doses of drug
Study: NCT01950949

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 300 ml Hydroxyethyl Starch 130/0.4 and Sodium Chloride Injection infusing in 15 minutes if PPV under VT 8 ml/kg was larger than 13% in the initial investigation
Study: NCT00057551

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Supportive Psychotherapy
Description: brief supportive psychotherapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBASP
Description: psychotherapy developed for chronic depression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medication Only
Description: antidepressant medication
Study: NCT01222325

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: extracorporeal shockwave lithotripsy (SWL)
Description: patients were submitted to one session SWL at a Dornier Compact Delta lithotripter under general anesthesia under supervision of an anesthesiologist and an urologist.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: extracorporeal shockwave lithotripsy (SWL)
Description: patients were submitted to one session SWL at a Dornier Compact Delta lithotripter under general anesthesia under supervision of an anesthesiologist and an urologist.
Study: NCT04073849

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EPOGEN® (epoetin alfa)
Description: Active drug

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Normal Saline
Description: Placebo
Study: NCT01949649

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peer-Led Group Intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet-Based Intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinician-Led Group Intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education Video
Study: NCT03308383

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DOING TRANSTHORACIC ECHOCARDIOGRAM
Description: TRANSTHORACIC ECHOCARDIOGRAM WILL BE DONE IN THE PARTICIPANTS WHICH IS NON-INVASIVE
Study: NCT01193283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 30 my/kg for 4 days
Study: NCT04081610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lagricel ofteno multidose
Description: * Dosage: 1 drop 4 times a day per 7 days, both eyes~* Route of administration: Ophthalmic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lagricel ofteno single dose
Description: * Dosage: 1 drop 4 times a day per 7 days, both eyes~* Route of administration: Ophthalmic
Study: NCT04523805

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted judo programme
Description: The judo sessions were 75 minutes in duration and were held once a week. Two judo teachers led each session, and at least four volunteer judo instructors were present to lend support. The sessions were divided into warm-up, main exercise and cool-down activities. The main exercise content of the sessions included:~* Different types of movements and falling techniques (from walking in all directions to turning around, from stable movements to unstable movements).~* Judo techniques and games (building up body contact with games, teaching simplified movements, essential judo movements) (blinded for review).~* Ground control techniques and throws (gradually adding techniques to already known movements, scaffolding basic repetitive movements to assist in understanding to those more relevant for judo ).~* Repetition of different forms of foundational directional movements (pulling, pushing, holding, lifting).
Study: NCT03510299

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mcgrath
Description: McGrath assisted insertion of LMA flexible

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Digital manipulation technique of LMA flexible insertion
Study: NCT01498484

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EBV-specific T cells (EBV-CTLs)
Description: EBV-CTLs are cytotoxic T lymphocytes that specifically kill cells presenting EBV protein antigens including EBV-transformed B lymphocytes responsible for EBV-associated lymphomas and lymphoproliferative disorders.
Study: NCT04547608

Intervention type: OTHER
Group type: OTHER
Intervention: The difference of the timing of rocuronium administration after propofol injection
Description: The difference of the timing was rocuronium was administered immediately after propofol injection or when BIS score became below 60 after propofol administration.

Intervention type: OTHER
Group type: OTHER
Intervention: The difference of the timing of rocuronium administration after propofol injection
Description: The difference of the timing was rocuronium was administered immediately after propofol injection or when BIS score became below 60 after propofol administration.
Study: NCT03330223

Intervention type: DEVICE
Intervention: Clopidogrel group;Ticagrelor group
Description: A total of 60 patients with ESRD and under dual-antiplatelet treatmen for at least 5 days will be enrolled and divided into the Clopidogrel group (clopidogrel 75mg qd;aspirin 100mg qd, n=30) and the Ticagrelor group (ticagrelor 90mg bid; aspirin 100mg qd, n=30). All included patients will receive haemodialysis by two different types of dialysis membrane.Platelet aggregation of venous blood from all patients will be detected by LTA and VerifyNow immediately before and after haemodialysis.

Intervention type: DEVICE
Intervention: Clopidogrel group;Ticagrelor group
Description: A total of 60 patients with ESRD and under dual-antiplatelet treatmen for at least 5 days will be enrolled and divided into the Clopidogrel group (clopidogrel 75mg qd;aspirin 100mg qd, n=30) and the Ticagrelor group (ticagrelor 90mg bid; aspirin 100mg qd, n=30). All included patients will receive haemodialysis by two different types of dialysis membrane.Platelet aggregation of venous blood from all patients will be detected by LTA and VerifyNow immediately before and after haemodialysis.
Study: NCT03221621

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wide Excision
Description: Wide excision is performed under general anaesthesia or procedural sedation and analgesia (PSA). All lesional tissue, including fibrosis, is electrosurgically removed until the area is clear. The subcutaneous fat and epithelised sinus floors are left intact where possible. The wounds are left open to heal by secondary intention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab Injection
Description: Adalimumab will be administered through subcutaneous injections in weekly dose of 40mg from week 4 up to 24 months (V8), after an initial dose of 160mg at week 0 and a 80mg dose at week 2 until end of study or last surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab Injection
Description: Adalimumab will be administered through subcutaneous injections in weekly dose of 40mg from week 4 up to 24 months (V8), after an initial dose of 160mg at week 0 and a 80mg dose at week 2 until end of study or last surgery.
Study: NCT01193283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: daily to a trough of 100 t0 200 ng/ml
Study: NCT00276783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: Administered intravenously at a dose of 900 mg/m2 every 21 days until disease progression.
Study: NCT01498484

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EBV-specific T cells (EBV-CTLs)
Description: EBV-CTLs are cytotoxic T lymphocytes that specifically kill cells presenting EBV protein antigens including EBV-transformed B lymphocytes responsible for EBV-associated lymphomas and lymphoproliferative disorders.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EBV-specific T cells (EBV-CTLs)
Description: EBV-CTLs are cytotoxic T lymphocytes that specifically kill cells presenting EBV protein antigens including EBV-transformed B lymphocytes responsible for EBV-associated lymphomas and lymphoproliferative disorders.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EBV-specific T cells (EBV-CTLs)
Description: EBV-CTLs are cytotoxic T lymphocytes that specifically kill cells presenting EBV protein antigens including EBV-transformed B lymphocytes responsible for EBV-associated lymphomas and lymphoproliferative disorders.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EBV-specific T cells (EBV-CTLs)
Description: EBV-CTLs are cytotoxic T lymphocytes that specifically kill cells presenting EBV protein antigens including EBV-transformed B lymphocytes responsible for EBV-associated lymphomas and lymphoproliferative disorders.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EBV-specific T cells (EBV-CTLs)
Description: EBV-CTLs are cytotoxic T lymphocytes that specifically kill cells presenting EBV protein antigens including EBV-transformed B lymphocytes responsible for EBV-associated lymphomas and lymphoproliferative disorders.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EBV-specific T cells (EBV-CTLs)
Description: EBV-CTLs are cytotoxic T lymphocytes that specifically kill cells presenting EBV protein antigens including EBV-transformed B lymphocytes responsible for EBV-associated lymphomas and lymphoproliferative disorders.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EBV-specific T cells (EBV-CTLs)
Description: EBV-CTLs are cytotoxic T lymphocytes that specifically kill cells presenting EBV protein antigens including EBV-transformed B lymphocytes responsible for EBV-associated lymphomas and lymphoproliferative disorders.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EBV-specific T cells (EBV-CTLs)
Description: EBV-CTLs are cytotoxic T lymphocytes that specifically kill cells presenting EBV protein antigens including EBV-transformed B lymphocytes responsible for EBV-associated lymphomas and lymphoproliferative disorders.
Study: NCT03496792

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tilt + external pressure
Description: In Visit 1, the anti-shock trousers will be inflated to 20, 40, or 60 mmHg. BP will be measured 3 times from the brachial artery. Then the table will be tilted head up to a maximum of 70o for up to 10 min, while BP will be measured from the brachial artery at 1 min intervals. The tilt table is returned to 0o and the resting supine baseline BP will be collected. Then, the anti-shock trousers will be inflated to a different pressure (20, 40, or 60 mmHg) and the head up tilt will be repeated. Repetitions at the various pressures will be performed in a random order with suitable resting intervals in between the tilting bouts.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Tilt + no external pressure.
Description: In Visit 1, the anti-shock trousers will NOT be inflated. Auscultatory BP will be measured 3 times from the brachial artery. Thereafter, the table will be tilted head up to a maximum of 70o for up to 10 min, while BP will be measured from the brachial artery at 1 min intervals.
Study: NCT04502576

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive respiratory support
Description: In both arms, the treatment according to the assigned protocol will be continued until the patient requires endotracheal intubation or (in case of no intubation) up to ICU discharge.~Patients will have to undergo the allocated treatment within 1 hour from the moment of randomization and within 24 hours from admission in the intensive care unit

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Noninvasive respiratory support
Description: In both arms, the treatment according to the assigned protocol will be continued until the patient requires endotracheal intubation or (in case of no intubation) up to ICU discharge.~Patients will have to undergo the allocated treatment within 1 hour from the moment of randomization and within 24 hours from admission in the intensive care unit